Physician profile
John A Kalin
NPI 1295783447
$447,603.44
in general payments reported to CMS, 2019-2025
40 companies · $21K in 2025
The $21K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131K · 2020: $60K · 2021: $75K · 2022: $41K · 2023: $46K · 2024: $73K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Honoraria: $42K · Food and Beverage: $11K · Travel and Lodging: $7,037 · Consulting Fee: $3,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,549.00 |
| Honoraria | $42,240.00 |
| Food and Beverage | $11,280.23 |
| Travel and Lodging | $7,037.10 |
| Consulting Fee | $3,224.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $131,911.37 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63,905.95 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $52,185.42 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $41,585.48 | 2019-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $41,429.28 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $26,464.73 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $22,442.65 | 2020-2025 | Jardiance, Mounjaro |
| Novartis Pharmaceuticals Corporation | $18,044.82 | 2019-2025 | |
| Astrazeneca Uk Limited | $13,337.77 | 2019 | |
| Pfizer INC. | $12,365.73 | 2019-2025 | |
| Amarin Pharma, INC. | $6,881.91 | 2019-2021 | |
| Scpharmaceuticals INC. | $6,458.48 | 2023-2025 | |
| Boston Scientific Corporation | $5,143.76 | 2019-2025 | Watchman, Watchman Flx, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,701.39 | 2019-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $596.32 | 2020-2025 | Onpattro, Amvuttra |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $586.60 | 2021-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $484.68 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $293.68 | 2021-2025 | |
| Medtronic, INC. | $217.54 | 2022-2023 | Linq II |
| Esperion Therapeutics, INC. | $215.36 | 2020-2025 | Nexletol |
| Irhythm Technologies, INC. | $194.87 | 2022-2024 | Zio Monitor, Zio Xt Patch |
| Regeneron Healthcare Solutions, INC. | $163.07 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $150.42 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Kowa Pharmaceuticals America, INC. | $134.91 | 2019-2021 | |
| Bardy Diagnostics, INC. | $110.00 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $79.42 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $62.69 | 2022-2023 | |
| Heartflow, INC. | $60.82 | 2024-2025 | |
| Baxter Healthcare | $56.25 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Medicomp INC | $46.21 | 2024-2025 | Telepatch Cardiac Monitor |
| Sensible Medical Innovations INC | $40.81 | 2024 | Reds System |
| Gilead Sciences, INC. | $38.11 | 2019 | |
| Abiomed | $37.89 | 2024 | Impella |
| Philips North America LLC | $35.34 | 2020 | |
| Janssen Scientific Affairs, LLC | $28.56 | 2022 | |
| Ge Healthcare | $28.37 | 2025 | |
| Abbott Laboratories | $27.13 | 2022 | |
| Covidien LP | $22.35 | 2019 | |
| Mannkind Corporation | $18.61 | 2025 | |
| Medtronic Vascular, INC. | $14.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kalin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.